這篇”新英格蘭醫學雜誌”刊登的文章，整理目前卡達(Qatar)使用輝瑞疫苗(Pfizer–BioNTech)碰上COVID 變異病毒的效用，應該就是前面哈佛醫學期刊引用的文章。
https://www.nejm.org/doi/full/10.1056/NEJMc2104974
卡達從去年12/21開始大規模施打Pfizer疫苗，到3/31為止共有385,853人至少打過一劑疫苗，其中265,410人打完兩劑.
引用:
|
Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
|
在2/23之後的COVID感染病例經基因定序後發現幾乎95%以上都是變異株病毒，B.1.351 or B.1.1.7都包括.
引用:
|
The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% (95% confidence interval [CI], 85.9 to 92.3) at 14 or more days after the second dose (Table 1 and Table S2). The effectiveness against any documented infection with the B.1.351 variant was 75.0% (95% CI, 70.5 to 78.9). Vaccine effectiveness against severe, critical, or fatal disease due to infection with any SARS-CoV-2 (with the B.1.1.7 and B.1.351 variants being predominant within Qatar) was very high, at 97.4% (95% CI, 92.2 to 99.5).
|
依據所有紀錄估計對B.1.1.7的免疫力為85.9%，對B.1.351為75%，而總體對防止感染發展變為重症的防禦率高達97.4%.
也就是說雖然對預防變異病毒感染的效力下降，但總體結果而言，即使感染後仍有高達97%以上的效力防止變為重症，